Islet Cell Transplant Clinical Trials

Trials Focus on Improving Transplant Safety and Long-Term Success

Though progress has been substantial, islet transplantation remains an experimental procedure. Islet transplant studies here at the DRI will continue to focus on improving the safety and long-term success of cell replacement therapies.

Our Clinical Cell Transplant Program has several active protocols that will:

  • Assess the safety and effectiveness of new drugs to prevent rejection
  • Assess the safety and effectiveness of other agents to improve islet engraftment and increase islet mass after transplantation
  • Assess the safety and effectiveness of co-transplanting selected immune cells to improve graft acceptance and promote long-term cell function
  • Identify markers that indicate early islet loss so we can develop intervention strategies to sustain islet function.

Current Clinical Trials:
We’re actively screening individuals for participation in the islet alone or islet after kidney transplantation studies.

1. Islet Cell Transplantation Alone in Patients with Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression*

2. Islet After Kidney Transplant

3. Strategies to Improve Long Term Islet Graft Survival

For additional information on the trials and/or eligibility criteria, please call 305-243-5321 or send an email. You can also print out and complete the Islet Transplant Application form and fax it to 305-243-1058.

The DRI collaborates with other researchers through the Clinical Islet Transplantation Consortium, a network of clinical centers and a data coordinating center established in 2004 to conduct studies of islet transplantation in patients with type 1 diabetes.

*GLP-1 analog medications will be initiated at time of islet infusion to evaluate their ability to enhance islet engraftment and long term function through their anti-apoptotic (cell protective) properties.

Also, participants that achieved insulin independence after islet transplantation but again require insulin, will be offered the opportunity to test the ability of  GLP-1 analog medications to increase islet mass and, potentially, restore insulin independence.